Catalent Biologics
在场
是其中之一......
Catalent Pharma Solutions 是一家在股票代码 CTLT (US) 下上市的公司。
Catalent Pharma Solutions 在 2 个国家有直接业务。Catalent Pharma Solutions 拥有 3家子公司，其中包括 Catalent Biologics、Catalent Cell & Gene Therapy 和 Catalent Pharma Germany。
他们在：
涉及Catalent Pharma Solutions的并购和融资。
- Novo Holdings has announced the acquisition of Catalent Pharma Solutions (公布2024二月8号).
高管
查看带有其 3 名主要高管的组织结构图
Catalent Biologics 搜索最多的简介
- David Mcerlane, Group President
- Jason Spacek, Vice President, Business Development
- Ricardo Zayas, Senior Vice President, Global Operations
创建提醒
跟踪 Catalent Biologics 的高管变动
生物技术
Catalent Pharma Solutions 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Catalent Biologics 的最新新闻稿
- IsomAb Announces Strategic Collaboration with Catalent
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
- Catalent and JLABS Symposium to Discuss Accelerated Development and Manufacturing of Biologics
- Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities
- Catalent to Present on Integrated UpTempo℠ Gene Therapy Development Platform
- Catalent & Bhami Research Laboratory Enter into Licensing Agreement
- Catalent Launches Case Management of Cell and Gene Therapies
- Sarepta and Catalent Expand Strategic Manufacturing Partnership
- Catalent to Expand Its Biologics Analytical Services with New Facility in Durham, North Carolina
- Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities
- View more press releases Close
通过电子邮件
